Psoriatic Arthritis Treatment Market to Exhibit 9.5% CAGR and Reach $13.12 Billion: Advanced Predictive Analytics offered by RCM to Boost Growth

The global psoriatic arthritis treatment market size is anticipated to touch USD 13.12 billion by the end of 2027 on account of the increasing prevalence of psoriatic arthritis. According to a published report by Fortune Business Insights titled, "Psoriatic Arthritis Treatment Market Size, Share & COVID-19 Impact Analysis, By Drugs Class (Non-steroidal Anti-inflammatory Drugs (NSAIDS), Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Others), By Route of Administration (Oral, Parenteral, and Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Regional Forecast, 2020-2027," the value of this market was USD 6.35 billion in the year 2019. The forecast period is set between 2020 and 2027 and the market is expected to rise at a CAGR of 9.5%.

Get Sample PDF Brochure:
https://www.fortunebusinessinsights.com/enquiry/sample/psoriatic-arthritis-treatment-market-101066

Most of the businesses today are affected by the coronavirus pandemic. The imposition of stringent government regulations for controlling the widespread use of this virus has majorly impacted the world economy. Some of the businesses that are operating from homes are barely able to generate meagre revenue.
Fortune Business Insights is offering detailed analysis on the impact of the COVID-19 pandemic on different markets. These reports will assist financers and other candidates to study the current situation and accordingly plan ahead of the future.

Geographical Analysis:
• North America (The U.S. and Canada)
• Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)
• Asia Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia Pacific)
• Latin America (Brazil, Mexico, and the Rest of Latin America)
• The Middle East & Africa (South Africa, GCC, and the Rest of the Middle East & Africa)
What is the Scope of the Report?
The report is based on a qualitative and quantitative analysis of the market and emphasizes mainly on drivers, restraints, challenges, and upcoming opportunities. It also discusses the key industry trends, current developments, and other insights into the market. The report also highlights the list of players operating in the market and their attributed factors. The report is available for sale on the company website.

To get to know more about the short-term and long-term impact of COVID-19 on this market,
Please Visit: https://www.fortunebusinessinsights.com/industry-reports/psoriatic-arthritis-treatment-market-101066

Drivers & Restraints
Rising Prevalence of Psoriasis Arthritis to Augment Growth
The growing geriatric population and the increasing prevalence of psoriatic arthritis are the key factors boosting the global psoriatic arthritis treatment market growth. This disease is likely to prevail in people leading a stressful lifestyle. This, coupled with the increasing affordability of biologic products and new product launches, will also contribute positively to the growth of the market.

On the negative side, the impact of the COVID-19 pandemic has reduced the urgency of other diseases and therefore hampered the growth of the market for psoriatic arthritis. Moreover, the high cost of biologic products used for treating this kind of disease may pose a major challenge to the growth of this market.

Nevertheless, the continuously rising patient pool and the increasing preference for the use of biological treatment products especially by dermatologists are likely to create lucrative growth opportunities for the market in the coming years.

Segmentation-
DMARDs Segment to Dominate Market Owing to Increasing Adoption of Biological Therapies
Among all drug class types, the biologic disease modifying anti-rheumatic drugs (DMARDs) segment earned the largest psoriatic arthritis treatment market share in 2019. This is accountable to the increasing adoption of biological therapies, a factor that is attributable to its efficacy towards disease management.

Speak To Our Analyst:
https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/psoriatic-arthritis-treatment-market-101066

Regional Analysis-
Rising Adoption of Biological Therapies to help North America Continue Dominating Market
Among all regions, North America accounted for the largest share on account of the massive investments in research and development of therapeutic options and coupled with the increasing adoption of biological therapies to treat psoriasis arthritis. Moreover, the presence of large manufacturers and the continuous number of clinical trials and drug approvals by the U.S. Food and Drug Administration will further help this region dominate the market in the coming years.
Europe ranks second in terms of market size whereas Asia Pacific market is likely to emerge as the fastest growing region in the forecast duration on account of the improving healthcare infrastructure, rise in medical expenditure, and the entry of novel biologics.

Competitive Landscape-
Players Focusing on Getting FDA Approvals of their Products to Stay Ahead in the Competition
The competitive landscape of the global psoriatic arthritis treatment market is consolidated in nature on account of the presence of a few players. Among them, AbbVie is holding the leading position in the market owing to its most popular brand, Humira used for treating psoriatic arthritis. Some of the other players are engaging in launching products and anticipating FDA approvals to gain a competitive edge in the market competition.

Industry Developments
December 2017 - The U.S. Food and Drug Administration permitted the use of Infliximab, an antibody for fighting diseases such as plague psoriasis, ankylosing spondylitis, Crohn's disease, and others.
August 2019 - Otezla was acquired by Amgen for USD 13.4 billion cash. This new therapy will help to strengthen the overall portfolio of Amgen.

List of Companies Profiled in the market for psoriatic arthritis treatment:
• Bayer AG (Leverkusen, Germany)
• Bristol-Myers Squibb Company (New York, United States)
• AstraZeneca (Cambridge, United Kingdom)
• Johnson & Johnson Services, Inc. (New Jersey, United States)
• Pfizer Inc. (New York, United States)
• Eli Lilly and Company (Indiana, United States)
• Novartis AG (Basel, Switzerland)
• GlaxoSmithKline plc. (Brentford, United Kingdom)
• Hoffmann-La Roche Ltd (Basel, Switzerland)
• Amgen (Califormia, United States)
• Sanofi (Paris, France)

Quick Buy - Psoriatic Arthritis Treatment Market Research Report:
https://www.fortunebusinessinsights.com/checkout-page/101066

About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
LinkedIn: https://www.linkedin.com/company/fortune-business-insights

This release was published on openPR.